The pathophysiological processes underlying Alzheimer's disease (AD) are hypothesized to begin years to decades before clinical symptom onset, while individuals are still cognitively normal. Although many studies have examined the effect of biomarkers of amyloid pathology on measures of cognitive performance, less is known about the effect of tau pathology on cognitive performance. The present study examined the association between cerebrospinal fluid (CSF) biomarkers of AD pathology (amyloid, total tau (t-tau), and phosphorylated tau (p-tau)) and cognition in a large sample of cognitively normal middle-aged and older adults. Associations were examined with multivariate regressions, in which either amyloid and t-tau or amyloid and p-tau were included as simultaneous predictors of cognitive performance. Cognitive performance was measured with three composite scores assessing working memory, verbal episodic memory, and visuospatial episodic memory. In their respective models, CSF measures of both t-tau and p-tau were associated with the visuospatial episodic memory composite score (po .001 and p¼.02, respectively), but not with the other measures of cognition. In contrast, CSF amyloid was not significantly associated with cognitive performance, raising the possibility that measures of tau pathology have a more direct relationship with cognition in cognitively normal individuals. These results also suggest that tau pathology may have effects on visuospatial episodic memory during preclinical AD that precede alterations in other cognitive domains.
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Introduction
Several lines of evidence suggest there is a preclinical phase of Alzheimer's disease (AD) during which AD pathology is accumulating (i.e., amyloid plaques and tau neurofibrillary tangles), in the absence of clinical symptoms (Sperling et al., 2011) . These pathophysiological processes are thought to begin years to decades before the onset of clinical symptoms of AD, when individuals are still cognitively normal. This conclusion is primarily based on evidence that a subset of older individuals who are cognitively normal have AD pathology in their brains, based on both autopsy findings (Bennett et al., 2006; Hulette et al., 1998; Knopman et al., 2003) and amyloid imaging studies (Morris et al., 2010; Rowe et al., 2010; Reiman et al., 2009) .
Moreover, recent studies suggest that cognitively normal individuals with biomarker evidence of AD pathology are at increased risk for developing cognitive decline over time. For example, cerebrospinal fluid (CSF) biomarkers of AD pathology (e.g., decreased levels of amyloid-beta (Aβ 1-42 ) and increased levels of total tau (t-tau) and phosphorylated tau (p-tau)) are associated with increased amyloid plaque burden and neurofibrillary tangle load at autopsy (Strozyk et al., 2003; Tapiola et al., 2009 ). Measured in cognitively normal individuals, these biomarkers are associated with increased risk for the development of clinical symptoms of AD (Fagan et al., 2007; Li et al., 2007; Roe et al., 2013; Moghekar et al., 2013) . Cognitively normal individuals who subsequently develop clinical symptoms of AD also tend to perform more poorly on cognitive tests prior to symptom onset than individuals who remain cognitively normal (Albert et al., 2014; Howieson et al., 2008 ; for a discussion, see Sperling et al., 2011) . This likely reflects the negative effect of AD pathology on cognition Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/neuropsychologia
